KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Current Deferred Revenue (2020 - 2021)

Castle Biosciences (CSTL) has disclosed Current Deferred Revenue for 2 consecutive years, with $3.0 million as the latest value for Q3 2021.

  • Quarterly Current Deferred Revenue fell 64.08% to $3.0 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Sep 2021, down 64.08% year-over-year, with the annual reading at $6.6 million for FY2020, N/A changed from the prior year.
  • Current Deferred Revenue hit $3.0 million in Q3 2021 for Castle Biosciences, down from $6.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $8.4 million in Q2 2020 to a low of $3.0 million in Q3 2021.